Toronto, ON

Monday November 12th &
Tuesday November 13th 2018


November 13, 2017
  • 7:30 AM
    Registration and Breakfast
  • 8:15 AM
    Opening Comments from the Chair
    Kaitlyn Proulx
    Managing Director, PDCI
  • 8:30 AM
    Keynote Address: PMPRB
    Assess Regulatory Changes to Determine Their Impact on Your Market Access Strategy
    Douglas Clark
    Executive Director, Patented Medicine Prices Review Board

    PMPRB Framework modernization is underway with significant changes pending to both the Patented Medicine’s Regulations and PMPRB Pricing Guidelines. Gather insights on:

    • The latest developments on Health Canada’s proposal to add new factors to the PMPRB’s price ceiling setting process.
    • How the PMPRB might operationalize these factors as part of its new risk-based approach to price regulation.

    Discover what regulatory changes can mean to your market access strategy.

  • 9:00 AM
    Panel Discussion: RWE
    Adopt Innovative Solutions in the Use of Real-world Evidence to Enhance your Decision-making
    Neil Corner
    General Manager - Real World Insight, QuintilesIMS
    Alison Paprica
    Director, Strategic Partnerships, Institute for Clinical Evaluative Sciences
    Sarah Lyons
    Chief Operating Officer, Privacy Analytics
    Brad Millson
    Principal, Health Access & Outcomes, QuintilesIMS

    Governments, payers and healthcare’s other stakeholders increasingly look to incorporate data to support decision-making. Explore innovation in Real-World Evidence to improve the value, efficacy and impact of medicines. Take away strategies to:

    • Enhance efficacy of your medicines on individual patient outcomes
    • Evaluate the impact on the health of the overall populations
    • Partner with your stakeholders to access data

    Prove and improve the value, efficacy and impact of your medicines with RWE.

  • 9:45 AM
    Health Canada
    Improving Access to Necessary Therapeutic Products
    Michèle Chadwick
    Lead, Regulatory Review of Drugs and Devices, Health Canada

    The Regulatory Review of Drugs and Devices (R2D2) initiative is underway. Review the objectives of this initiative to improve access to therapeutic products  Stay up-to-date on:

    • Expanded collaboration with health partners
    • More timely access to drugs and devices
    • Enhanced use of real word data

    Analyze the R2D2 initiative to bolster access to treatment

  • 10:15 AM
    Morning Break
  • 10:35 AM
    Panel Discussion: Oncology drug HTA
    Assess Stakeholders’ Perspectives on HTA Process to Improve Your Submissions
    Deborah Maskens
    Founder, Kidney Cancer Canada
    Laurene Redding

    With pCODR review and possible re-review, patients can wait 2 to 4 years for access to innovative cancer treatments. Advance your submission strategy to include broader stakeholder insights. Source Intelligence to:

    • Review current HTA processes, timelines, potential delays
    • Understand the new patient and clinician input processes to pCODR
    • Assess the impact of provincial re-review and pCODR Request for Advice (RFA) on access

    Review the effect of all stakeholder submissions to better strategize your market access strategy

  • 11:20 AM
    Patient Advocacy
    Patient Need Access to the Right Treatment at the Right Time
    Lorna Warwick
    Director, Strategic Communications & Engagement, Lymphoma Coalition

    Reconciling the urgency of patient need with a thorough HTA process is a growing a challenge. Explore what patients expect from you to improve patient outcomes. Gain insights to:

    • What patient centricity means to the end user (the patient)
    • Refine your stakeholder mapping
    • Advance your stakeholder engagement process

    Ensure the patients are at the centre of your strategic planning

  • 11:50 PM
    Panel Discussion: Private Payers
    Analyze Emerging Trends Among Private Payers and Adapt to Change
    Chris Goguen
    Strategic Pharmaceutical Partnerships Lead, Medavie Blue Cross
    Barbara A. Martinez
    National Practice Leader, Drug Benefits Solutions, Great West Life
    Karen Voin
    Assistant Vice President - Group Benefits and Anti-Fraud, Canadian Life and Health Insurance Association

    The private payer landscape is undergoing significant changes that will impact patient access and how medications are reimbursed. Strengthen your market access strategy with insights into emerging trends in the private payer landscape. Source critical information to:

    • Assess trends among large employers
    • Revise changes in industry leadership and emerging partnerships
    • Review the solutions plan sponsors are considering

    Integrate the employer’s outlook into your market access strategies.

  • 12:30 PM
    Networking Lunch
  • Common Drugs
    • 1:30 PM
      Case Study: New Product Pricing
      Increase Patient Access with Differential Pricing Considerations
      Rosemarie Childerhose
      Lead, Patient Relations and Government Relations, Valeant Pharmaceuticals

      In a highly regulated pricing market pharmaceutical companies look to incorporate differential pricing domestically to increase patient access. Review how to approach Canadian “differential pricing” to increase patient access. Gain insights to:

      • Analyze how price impact patient’s ability to choose a product that best meets her/his needs
      • Price your products while addressing changing market expectations
      • Increase access to priority products with portfolio pricing in different markets

      Join us for a timely and stimulating discussion that will inform your pricing strategy development for future launch products.

    • 2:00 PM
      Case Study: Managing Data
      Structure your Data from Real-world Setting to Enhance your Value Proposition
      Karine Alloul
      Senior Manager, Health Economics & Health Outcomes, Sanofi

      Real-world evidence can be a challenge due to the complexity of the data. Learn from Sanofi’s experience to strategize your data management. Gain practical tips to:

      • Address specific patient outcomes within your researches
      • Analyze the impact of RWE on your submission/li>
      • Review your value proposition

      Gain practical insights on the challenges of RWE from Sanofi’s experience.

    Speciality Drugs – Oncology
    • 1:30 PM
      Case Study: ODANO
      Analyze ODANO’s Work with Patients to Anticipate the Demand Side of the Market
      Alan Birch
      Drug Access Navigator, ODANO

      ODANO is a new Ontarian drug access navigator to facilitate cancer drug coverage. Analyze the impact of drug access navigators on patients to increase speed of reimbursement. Gain insights on:

      • Educating patients
      • Establishing and enhancing partnerships
      • Best practice sharing among patients

      Explore what drug access navigators can do to increase the speed of reimbursement.

    • 2:00 PM
      Oncology Biosimilars
      Market Access considerations for Biosimilars
      Heather Francis
      Director of Healthcare and Innovation, Roche Canada

      The next wave of biosimilars is about to enter the Canadian market and present unique issues not part of the current landscape. Learn about the considerations associated with institutionally-based products such as oncology monoclonal antibodies, including:

      • Pharmaceutical policy related to reimbursement
      • Regulatory review, naming convention, health technology assessment, and public funding
      • Key differences related to levels of evidence, switching and funding mechanisms

      Assess the considerations for Oncology biosimilars.

  • 2:30 PM
    Setting the Tone – A Renewed Approach
    Collaborate with Key partners to Improve Access and Affordability of Medicines
    Pamela Fralick
    President, Innovative Medicines Canada

    Collaboration is key to stimulate the life sciences sector in our country. Meet shared objectives with public partners to advance access and affordability.

  • 3:00 PM
    Afternoon Break
  • 3:30 PM
    Regional Health Authority
    Assess the National Formulary Collaborative (NFC) from the Perspective of Alberta’s Regional Health Authority
    Jeremy Slobodan
    Director, Drug Utilization, Information & Stewardship, Alberta Health Services

    Regional health authorities are working to improve alignment with public drug plans and utilize the best available evidence when reviewing hospital only drugs. Analyze the NFC and the hospital formulary review process in Alberta to improve your market access strategy. Gain insights to:

    • Review NFC, its purpose and its impact on manufacturers and payers
    • Comprehend policy alignment with CADTH and Alberta Drug Benefit List
    • Provide an overview of the formulary review process in Alberta and the challenges for coverage

    Evaluate the evolution of decision-making at the regional level and its effects on your organization. 

  • 4:00 PM
    Panel Discussion: Companion Diagnostic Tests
    Anticipate a Need to Include Relevant Companion Diagnostics Tests with Your New Drug Submissions
    Greg Rutherford
    Director - Pharmaceutical Solutions, McKesson Canada
    Christopher Trevors
    National Director - Genetic Health Solutions, Dynacare
    John Anacleto
    Director of Payer Relations, McKesson Canada

    CDR guideline are likely to change and major lab diagnostic testing companies and patient support programs are pro-acting for this eventuality. Adapt to changing CDR guidelines and Improve your submissions with companion diagnostic tests. Source intelligence to:

    • Highlight changes to CDR
    • Discuss commercialization of companion diagnostics
    • Review how payers intend to integrate these requirements into their coverage plans

    Strengthen your new submission with relevant companion diagnostic tests.

  • 4:45 PM
    Afternoon Keynote: British Columbia Update
    Align your Strategy with the Payer Policies to Increase the Speed of Reimbursement
    Mitch Moneo
    Assistant Deputy Minister, BC Ministry of Health

    With long negotiations and shrinking budgets, patients are likely to wait longer to get reimbursed. Stay in tune with payer priorities to ensure that your patients are quickly reimbursed. Develop your action plan to:

    • Clarify coverage criteria
    • Define and demonstrate value to the payers
    • Advance your listing agreements

    Adapt your value proposition to ensure the coverage of your treatments.

  • 5:25 PM
    Conference Adjourns to Day Two
  • 5:30 PM
    Executive Evening Reception
November 13, 2017
November 14, 2017
  • 7:00 AM
    Registration and Breakfast
  • 8:15 AM
    Opening Comments from the Chair
    John-Paul Dowson
    Managing Director, Roubaix Strategies Inc
  • 8:30 AM
    Keynote: pCPA Update
    Review pCPA Approach to Negotiation and Pricing to Prepare your Submissions Better
    Imran Ali
    Senior Manager, pan-Canadian Pharmaceutical Alliance
    Brad Alyward
    Manager, Business Solutions, Nova Scotia Department of Health and Wellness

    The pCPA changed notably in the past few years and its approach to negotiation has evolved. Reassess your expectation and improve your submissions. Source Intelligence to:

    • Enhance the use of your company’s research and marketing resources
    • Improve consistency of decisions and achieve lower drug costs
    • Facilitate communication between your company, the federal government and the provinces

    Revise changes at pCPA to enhance your submission process.

  • 9:30 AM
    Panel: Data Insights
    Advance Evidence Generation to Improve your Organization’s Access to Market
    Alison Drinkwater
    Senior Director, Strategic Consulting, Innomar Strategies
    Janey Shin, MSc M.B.A
    Director, Real World Evidence Government Affairs and Market Access, Janssen Inc.
    Marion McLean
    Senior Manager, Patient Assistance Services, AstraZeneca Canada
    Ferg Mills
    Director Health Economics, InnomarConsulting

    The trends occurring in the public and private plan designs are essential to developing your market access strategy. Leverage data insights within the patient support program environment to move from a reimbursement focus to an evidence generation focus. Discover insights to:

    • Link plan design with patient access
    • How patient support programs can generate Real World Evidence in decision making
    • Identify the trends that affect different products

    Analyze how the changing reimbursement landscape is impacting market access to optimize your company’s access strategies.

  • 10:00 AM
    Morning Break
  • 10:30 AM
    Quebec Update
    Healthcare Policy Changes to Improve Your Access and Lower Your Costs
    Dr. Luc Boileau
    President and Chief Executive Officer, Institut national d’excellence en santé et services sociaux (INESSS)
  • 10:45 AM
    Everything You Always Wanted to Know about Quebec’s Market Access but Afraid to Ask!
    Alain Madgin
    Senior Vice President, Citoyen Optimum
    Sebastien Beauchamp
    Vice President, Government Affairs, Public Policy & Market Access, Baxter

    Since the 2014 general election, the Quebec Government has shown the desire to proceed with major cut backs in the healthcare system. Wide-ranging reforms, aimed at conclusively fixing Quebec’s health system, are impacting service providers, manufacturers, healthcare professionals, and patients. Explore how your organization can position itself in this turbulent time. Master the success factors to:

    • Understand the regulatory framework in place and the policy environment;
    • Explore future issues and challenges;
    • List your projects in the government's vision.

    List your projects in the government's vision.

  • 11:30 AM
    Case Study: Orphan Drugs
    Collaborate with Stakeholders to Develop your Products and Improve Patient Outcomes
    Eric Tse
    General Manager, Canada, Shire Pharmaceutical

    Small markets can impede the development of orphan drugs, but collaboration can alleviate some restraints. Build partnerships to develop your new products and secure revenue opportunities. Build a roadmap to:

    • Explore funding and joint research opportunities
    • Gather inputs from patients
    • Optimize your company’s ROI in a small market

    Work with your stakeholders to increase patient access to treatments.

  • 12:00 PM
    Industry Expert: National Pharmacare
    Prospects for National Pharmacare
    Neil Palmer
    Founder & Principal Consultant, PDCI

    National Pharmacare continues to be the focus of research studies and political initiatives. Analyze the issues and offer a critical assessment of the latest research and the prospects for universal coverage of prescription medicines in Canada. Gain insights on:

    • Defining national pharmacare
    • Critical assessment of research studies
    • Influence of OHIP+ on the national discussion
    • Federal PBO analysis
    • Getting to the core issues of coverage & cost savings

    Review the latest research and the prospects for universal coverage of prescription medicines in Canada.

  • 12:30 PM
    Networking Lunch
  • Generic Drugs
    • 1:45 PM
      Case Study: Entering the Market
      Refine your Commercial Strategy to Secure Access to the Generic Drugs Market
      Mark Lachovsky
      President, Accel Pharma

      As payers aim at reducing costs, the focus on the generic drugs market is increasing. Improve your strategy to ensure access to the generic drugs market. Source intelligence on: 

      • Key historical issues
      • Current trends affecting utilization
      • Pricing challenges

      Learn from a unique approach to entering the market

    Brand Drugs
    • 1:45 PM
      Payer Partnerships
      Optimize your Access When Negotiating With Group Purchasing Organizations
      Doug Nanton
      Market Access & Government Affairs -Western Canada & Ottawa, Valeant Canada

      The growing transparency at CADTH and shrinking hospital budgets are changing the perspective of GPOs. Adapt to GPO’s approach to ensure your access to hospital and community care. Create a roadmap to:

      • Analyze the work of hospital review boards within GPOs
      • Clarify purchase criteria
      • Address cost concerns

      Overcome the challenges of shrinking government budgets when dealing with GPOs.

  • 2:30 PM
    Update on Biosimilar Uptake and Access Landscape in Canada
    Nadia Turchetta
    Executive Director of Biosimilars, Sandoz Canada
  • 3:30 PM
    Conference Adjourns
November 14, 2017
November 15, 2017
  • 9:00 AM - 12:00 PM
    Workshop A: Price Listing Agreement
    Drive Successful pCPA Strategies and PLAs to Solidify your Market Access Strategies
    Colin Vicente
    Managing Director, Pivina

    The pan-Canadian Pharmaceutical Alliance (pCPA) has established their officce and become a formal process for getting new drugs to the market. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:

    • Understand the pCPA process and submissions
    • Prepare for pCPA in the planning stages of your products
    • Use pricing models to assist your product’s positioning during negotiations
    • Gain an understanding of different types of Canadian PLAs
    • Take advantage of potential opportunities in private sector PLAs

    Develop your successful pCPA strategy through this hands-on interactive workshop.

November 15, 2017

Download Brochure - Gain new ideas and practical strategies for implementation

  • This field is for validation purposes and should be left unchanged.